Jeffrey S. Martini - Dec 13, 2024 Form 3 Insider Report for PALVELLA THERAPEUTICS, INC. (PVLA)

Role
Chief Scientific Officer
Signature
/s/ Kathleen A. McGowan, Attorney-in-Fact
Stock symbol
PVLA
Transactions as of
Dec 13, 2024
Transactions value $
$0
Form type
3
Date filed
12/16/2024, 07:42 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PVLA Stock Option (right to buy) Dec 13, 2024 Common Stock 32.3K $9.08 Direct F1
holding PVLA Stock Option (right to buy) Dec 13, 2024 Common Stock 10.2K $9.79 Direct F2
holding PVLA Stock Option (right to buy) Dec 13, 2024 Common Stock 18.5K $9.79 Direct F2
holding PVLA Stock Option (right to buy) Dec 13, 2024 Common Stock 13.3K $7.53 Direct F3
holding PVLA Stock Option (right to buy) Dec 13, 2024 Common Stock 6.61K $7.53 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested.
F2 The stock option vests in equal monthly installments over a forty-eight month period. The option was granted on February 23, 2023.
F3 The stock option vests in equal monthly installments over a forty-eight month period. The option was granted on May 28, 2024.